Sartor O - Search Results

1

Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.

Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Bennett CL, et al. Among authors: sartor o. J Clin Oncol. 2002 Sep 1;20(17):3599-604. doi: 10.1200/JCO.2002.11.085. J Clin Oncol. 2002. PMID: 12202660

2

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794

3

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Among authors: sartor o. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

4

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Among authors: sartor o. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

5

Mutated androgen receptors of prostate-cancer cells.

Figg WD, Middleman M, Sartor O. Figg WD, et al. Among authors: sartor o. N Engl J Med. 1995 Oct 12;333(15):1010-1. doi: 10.1056/NEJM199510123331516. N Engl J Med. 1995. PMID: 7666906 No abstract available.

6

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Dawson NA, et al. Among authors: sartor o. Cancer. 1995 Aug 1;76(3):453-62. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. Cancer. 1995. PMID: 8625127 Clinical Trial.

7

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.

Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Middleman MN, et al. Among authors: sartor o. Cancer Treat Rev. 1996 Mar;22(2):105-18. doi: 10.1016/s0305-7372(96)90030-4. Cancer Treat Rev. 1996. PMID: 8665563 Review. No abstract available.

8

Mifepristone: antineoplastic studies.

Sartor O, Figg WD. Sartor O, et al. Clin Obstet Gynecol. 1996 Jun;39(2):498-505. doi: 10.1097/00003081-199606000-00023. Clin Obstet Gynecol. 1996. PMID: 8734014 Review.

9

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.

Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Figg WD, et al. Among authors: sartor o. Cancer Invest. 1996;14(6):513-7. doi: 10.3109/07357909609076896. Cancer Invest. 1996. PMID: 8951355

10

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.

Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. Bowden CJ, et al. Among authors: sartor o. Cancer Chemother Pharmacol. 1996;39(1-2):1-8. doi: 10.1007/s002800050531. Cancer Chemother Pharmacol. 1996. PMID: 8995493 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

524 results

Search Page

Filters